VIRGINIA RETIREMENT SYSTEMS ET Al Makes New Investment in LivaNova PLC $LIVN

VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of LivaNova PLC (NASDAQ:LIVN) in the 2nd quarter, Holdings Channel.com reports. The fund acquired 38,041 shares of the company’s stock, valued at approximately $1,713,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Nordea Investment Management AB boosted its stake in shares of LivaNova by 2.4% during the second quarter. Nordea Investment Management AB now owns 103,264 shares of the company’s stock valued at $4,648,000 after purchasing an additional 2,402 shares during the period. CWM LLC boosted its stake in shares of LivaNova by 533.4% during the second quarter. CWM LLC now owns 5,517 shares of the company’s stock valued at $248,000 after purchasing an additional 4,646 shares during the period. Aberdeen Group plc boosted its stake in shares of LivaNova by 18.1% during the second quarter. Aberdeen Group plc now owns 326,786 shares of the company’s stock valued at $14,712,000 after purchasing an additional 50,076 shares during the period. KLP Kapitalforvaltning AS boosted its stake in shares of LivaNova by 10.9% during the second quarter. KLP Kapitalforvaltning AS now owns 12,200 shares of the company’s stock valued at $549,000 after purchasing an additional 1,200 shares during the period. Finally, Chapin Davis Inc. boosted its stake in shares of LivaNova by 15.3% during the second quarter. Chapin Davis Inc. now owns 19,600 shares of the company’s stock valued at $882,000 after purchasing an additional 2,600 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Wall Street Zen raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 9th. Needham & Company LLC reissued a “buy” rating and set a $64.00 target price on shares of LivaNova in a research note on Wednesday, September 3rd. The Goldman Sachs Group set a $55.00 target price on shares of LivaNova and gave the company a “neutral” rating in a research note on Wednesday, October 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of LivaNova in a research note on Wednesday, October 8th. Finally, Barclays boosted their target price on shares of LivaNova from $55.00 to $58.00 and gave the company an “equal weight” rating in a research note on Thursday, August 21st. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, LivaNova presently has a consensus rating of “Moderate Buy” and an average price target of $59.71.

LivaNova Stock Performance

Shares of LivaNova stock opened at $54.85 on Thursday. The company has a market capitalization of $2.99 billion, a PE ratio of -14.10 and a beta of 0.95. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.09 and a current ratio of 1.29. The company has a 50-day simple moving average of $54.50 and a two-hundred day simple moving average of $46.67. LivaNova PLC has a one year low of $32.48 and a one year high of $58.91.

LivaNova (NASDAQ:LIVN) last announced its earnings results on Wednesday, August 6th. The company reported $1.05 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.21. The business had revenue of $352.50 million during the quarter, compared to the consensus estimate of $332.20 million. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The firm’s revenue was up 10.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.93 earnings per share. Research analysts expect that LivaNova PLC will post 2.85 EPS for the current fiscal year.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.